{
    "nct_id": "NCT04833582",
    "official_title": "A Phase 1/2 Dose Escalation and Dose Expansion Study of ZN-c3 in Combination With Gemcitabine in Adult and Pediatric Subjects With Relapsed or Refractory Osteosarcoma",
    "inclusion_criteria": "* Age ≥ 12 years at the time of informed consent\n* Bodyweight ≥ 40 kg\n* Histologically documented relapsed or metastatic osteosarcoma.\n* Must have measurable disease according to RECIST Guideline version 1.1 criteria.\n* Adequate hematologic and organ function.\n* Female subjects of childbearing potential and male subjects must agree to use an effective method of contraception per institutional standard prior to the first dose and for 6 months after study treatment discontinuation.\n* Willingness and ability to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures.\nHealthy volunteers allowed\nMust have minimum age of 12 Years",
    "exclusion_criteria": "* Unresolved toxicity of Grade >1 attributed to prior therapies (excluding: Grade ≤2 neuropathy, alopecia, or skin pigmentation)\n* Prior therapy with a WEE1 inhibitor\n* A serious illness or medical condition(s).\n* Pregnant or lactating females. Females of childbearing potential with a positive serum pregnancy test <14 days to Day 1.\n* Subjects with active (uncontrolled, metastatic) second malignancies or requiring therapy.\n* 12-lead ECG demonstrating a corrected QT interval using Fridericia's formula (QTcF) of >470 ms, except for subjects with atrioventricular pacemakers or other conditions (e.g., right bundle branch block) that render the QT measurement invalid.\n* History or current evidence of congenital or family history of long QT syndrome or Torsades de Pointes (TdP).\n* Taking medications with a known risk of TdP.\n* Administration of strong and moderate CYP3A4 inhibitors/inducers and strong and moderate P-gp inhibitors.",
    "miscellaneous_criteria": ""
}